Results from the late-breaking TWILIGHT trial suggest that, among high-risk patients who have undergone PCI and completed three months of dual antiplatelet therapy, it’s safer to continue treatment with ticagrelor alone rather than add aspirin to that cocktail.

Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.

Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

Researchers on the International Space Station are leveraging the microgravity conditions within the ISS U.S. National Laboratory to study heart cells in ways we can’t on the ground.

A commonly prescribed drug used to treat attention-deficit/hyperactivity disorder (ADHD) disproportionately affects the development of children’s brains compared to adults with ADHD, according to a new study published in Radiology.

LEIPZIG and MARLBOROUGH, Mass. (January 22, 2019) — Boston Scientific (NYSE: BSX) today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically significant lower rates of target lesion revascularization (TLR) and stent thrombosis when compared to those treated with the Zilver® PTX® Drug-Eluting Peripheral Stent. 

Ambra Health, makers of the leading cloud-based, medical image management suite, today announced a new collaboration with Google Cloud to advance healthcare research with anonymized medical imaging data.